Riskpilot← Back to searchSign inGet full accessChr. Olesen Pharma Latin A/S
A/SActiveCVR 39463989Jægersborg Alle 164Wholesale of pharmaceutical and medical goods · NACE 4646Est. 2018— employeeswww.chr-olesen.dk
Revenue 2025
DKK 283K
-42% vs 2024
EBITDA margin
68.1%
-52% vs 2024
Equity ratio
25.0%
Financial strength
Net profit 2025
DKK 107K
-58% vs 2024
| Revenue | DKK 283K | -42% |
| EBITDA | DKK 193K | -52% |
| Net profit | DKK 107K | -58% |
| Total assets | DKK 2,9M | -22% |
| Equity | DKK 723K | -29% |
| Employees | — | — |
Legal name
Chr. Olesen Pharma Latin A/S
CVR number
39463989
Legal form
Aktieselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
1. april 2018
Share capital
DKK 500.000
Employees
—
VAT registered
Yes
Audit selected
Yes
Last report
2025-09-30
Financial year
January – December
Signatory rights
Virksomheden tegnes af direktøren
Company purpose
Virksomhedens formål er at drive handel med intermediates og API'er primært til dyr.
Address
Jægersborg Alle 164
Phone
+4570230700
Email
info@chr-olesen.dk
Website
www.chr-olesen.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 367 | 560 | 402 | 490 | 283 |
| Staff expenses | -0 | -0 | -73 | -87 | -90 |
| EBITDA | 367 | 560 | 329 | 403 | 193 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | 367 | 560 | 329 | 403 | 193 |
| Net financials | -56 | -77 | -132 | -79 | -55 |
| Profit before tax | 311 | 484 | 197 | 324 | 138 |
| Tax | 68 | 106 | 44 | 71 | 30 |
| Net profit | 243 | 377 | 153 | 253 | 107 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 3.707 | 2.894 | 3.194 | 3.688 | 2.892 |
| Equity | 632 | 1.009 | 863 | 1.015 | 723 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 3.075 | 1.885 | 2.331 | 2.673 | 2.170 |
| Total debt | 3.075 | 1.885 | 2.331 | 2.673 | 2.170 |
EBITDA margin
68.1%
This company
15.8%
Market median
+331% vs market
20212025
Equity ratio
25.0%
This company
38.2%
Market median
-35% vs market
20212025
Return on equity
14.8%
This company
18.4%
Market median
+20% vs market
20212025
Net profit margin
37.9%
This company
8.1%
Market median
+368% vs market
20212025
Asset turnover
0.10×
This company
1.12×
Market median
-91% vs market
20212025
Debt / equity
3.00×
This company
0.62×
Market median
-384% vs market
20212025
- Annual report 2025Filed via CVR / Virk · Period 2024-10-01 – 2025-09-30
- Annual report 2024Filed via CVR / Virk · Period 2023-10-01 – 2024-09-30
- Annual report 2023Filed via CVR / Virk · Period 2022-10-01 – 2023-09-30
- Annual report 2022Filed via CVR / Virk · Period 2021-10-01 – 2022-09-30
- Annual report 2021Filed via CVR / Virk · Period 2020-10-01 – 2021-09-30
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
MC Management | Management | 2026 |
PC Management | Management | 2023 |
CD Chief Executive Officer | Chief Executive Officer | 2026 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2018 | |
| Board of Directors | 2018 | |
| Board of Directors | 2018 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 50–66.65% | 50–66.65% | 2018 | |
| Individual | 25–33.32% | 25–33.32% | 2018 | |
| Individual | 10–14.99% | 10–14.99% | 2018 | |
| Individual | 10–14.99% | 10–14.99% | 2018 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Chr. Olesen Holding II A/SCHR. OLESEN HOLDING A/SCHR. OLESEN A/S
Chr. Olesen Pharma Latin A/S (this company)Board members of Chr. Olesen Pharma Latin A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mads Christian Olesen | Management | 0 companies |
| Phillip Christian Dam Quitzau Olesen | Management | 0 companies |
| Christian Dam Olesen | Chief Executive Officer | 0 companies |
| Allan Ardensø | Board of Directors | 0 companies |
| Alice Louise Wedell-Neergaard | Board of Directors | 0 companies |
| Steen Meldgaard Astrup | Board of Directors | 0 companies |